Pharmaceuticals APAC

APAC Endometriosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Endometriosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $312.0 Mn Placeholder estimate
Estimate 2025 $339.8 Mn 18.2% of the global market
Projected 2034 $731.9 Mn 115.4% Adds $392.1 Mn over 9 forecast years
CAGR 2025–2034 8.9% Faster than 44% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 18.21% of the global market.
  • Among regions, the largest is North America at $853.2 Mn.
  • Fastest growing: Africa at 9.8% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$392.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Endometriosis Treatment Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $312.0 Mn — —
2025 (base) $339.8 Mn +$27.8 Mn —
2026 (forecast) $370.0 Mn +$30.2 Mn +8.9%
2027 (forecast) $402.9 Mn +$32.9 Mn +18.6%
2028 (forecast) $438.8 Mn +$35.9 Mn +29.1%
2029 (forecast) $477.9 Mn +$39.1 Mn +40.6%
2030 (forecast) $520.4 Mn +$42.5 Mn +53.2%
2031 (forecast) $566.7 Mn +$46.3 Mn +66.8%
2032 (forecast) $617.1 Mn +$50.4 Mn +81.6%
2033 (forecast) $672.1 Mn +$54.9 Mn +97.8%
2034 (forecast) $731.9 Mn +$59.8 Mn +115.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Endometriosis Treatment Market Analysis at a glance
Market size, 2025$339.8 Mn placeholder estimate
Forecast, 2034$731.9 Mn placeholder estimate
Growth (CAGR), 2025–20348.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, drug and end user (see all)
Key playersAbbVie Inc., Bayer AG, Pfizer Inc., Myovant Sciences (Sumitomo Pharma), Kissei Pharmaceutical (see all)
Active clinical trials20 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Endometriosis Treatment Market Analysis Executive Summary

Endometriosis treatment relieves pain and protects fertility in women whose womb lining tissue grows outside the womb.

Key segments of the endometriosis Treatment market include treatment (Hormonal Therapy, GnRH Antagonists and Pain Relief) and drug (Relugolix Combination, Elagolix and Dienogest).

Bar chart: Asia Pacific Endometriosis Treatment market size, 2024–2034, placeholder estimates. $312.0 Mn in 2024, $339.8 Mn in 2025 and $731.9 Mn in 2034, 8.9% CAGR.
Asia Pacific Endometriosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Endometriosis Treatment Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the endometriosis Treatment market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the endometriosis Treatment market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the endometriosis Treatment market.

Competitive Landscape for Endometriosis Treatment Market in APAC

The endometriosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Endometriosis Treatment Market in APAC

Endometriosis Treatment in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 20 studies on Endometriosis Treatment that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for endometriosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Endometriosis Treatment right now, from free public sources.

Clinical trials

20 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Sumitomo Pharma 3 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Ziwig 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Samphire Group, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. EDAP TMS 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Endometriosis Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Endometriosis Treatment market in Asia Pacific?
Placeholder estimate: about $339.8 Mn in 2025, rising to about $731.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Endometriosis Treatment market in Asia Pacific growing?
Placeholder estimate: about 8.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Endometriosis Treatment market report cover?
The report splits the market by treatment (Hormonal Therapy, GnRH Antagonists, Pain Relief, Surgery), drug (Relugolix Combination, Elagolix, Dienogest, Others) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Endometriosis Treatment market?
Key players include AbbVie Inc., Bayer AG, Pfizer Inc., Myovant Sciences (Sumitomo Pharma) and Kissei Pharmaceutical.
What is driving the Endometriosis Treatment market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the endometriosis Treatment market. New products designed around women's biology and digital care are improving access.
How many clinical trials on Endometriosis Treatment are running in Asia Pacific?
20 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Endometriosis Treatment?
PubMed lists 175 papers on Endometriosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on women's health

See the topic